Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada 3
|
|
- Christiana Gardner
- 6 years ago
- Views:
Transcription
1 he Cardiovascular Safety of Aromatase Inhibitors and amoxifen in Post-Menopausal Women with Breast Cancer: A Systematic eview and Meta-Analysis of andomized Controlled rials Farzin Khosrow-Khavar MSc 1,2, Kristian B. Filion PhD 1,2,3, Shatha Al-Qurashi MD 4, Nazi orabi MLIS 5, Nathaniel Bouganim MD 6, Samy Suissa PhD 1,2, Laurent Azoulay PhD 1,2,4 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada 2 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada 3 Division of Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada 4 Department of Oncology, McGill University, Montreal, Quebec, Canada 5 McGill Library, McGill University, Montreal, Quebec, Canada 6 Department of Oncology, Cedar Cancer Center, McGill University Health Center, Montreal, Quebec, Canada NOYCIA 2016
2 Background Aromatase inhibitors () and tamoxifen are widely used in treatment of post-menopausal women with hormonereceptor positive breast cancer Meta-analysis indicate better efficacy associated with s in Cs directly comparing s to tamoxifen However, these studies also indicate increased risk of cardiovascular adverse events associated with s
3 Burstein HJ et al., JCO 2014 American Society of Clinical Oncology Guidelines
4 Cardioprotective Mechanisms of amoxifen amoxifen decreases levels of total cholesterol, LDL-C, and increases HDL-C levels in Cs amoxifen decreases levels of C-reactive protein and fibrinogen amoxifen has anti-oxidant activities which protect cholesterol from harmful oxidation
5 Objectives o conduct a comprehensive systematic review and meta-analysis of cardiovascular safety of s and tamoxifen Adjuvant rials Extended-Adjuvant rials Upfront vs P vs P vs Sequential P vs P Upfront vs P P Years Years
6 Methods Search Strategy: -Databases: Pubmed, Embase, Cochrane CENAL, WHO ICP, Clinicaltrials.gov -Population: Female -Intervention: Aromatase Inhibitors (letrozole, anastrozole, exemestane) or tamoxifen -British Medical C Hedge where appropriate Inclusion Criteria: -Population: Post-menopausal women with diagnosis of breast-cancer -Outcome: Studies reporting cardiovascular events (excluding VE, hypertension, hypercholesterolemia) Exclusion Criteria: -1 st or 2 nd generations s or raloxifene -Pre-menopausal population -Primary prevention trials -Less 100 patients -Studies where primary indication for endocrine therapy is not breast cancer
7 Quality Assessment and Analysis Quality Assessment: Cochrane collaboration tool for assessing risk of bias Screening and quality assessment conducted independently by two reviewers Analysis: elative risk of cardiovascular adverse events obtained for each C Pooled analysis by C design using DerSimonian-Laird andom- Effects Analysis Secondary analysis: Ischemic heart disease as the outcome Sensitivity Analysis: Fixed-effects analysis
8 Study Flow Diagram Embase (n=5537) PubMed (n=3028) WHO ICP (n=1290) Cochrane CENAL (n=4995) Clinicaltrials.gov (n=502) ecords identified through database search (n=15352) Duplicates (n=5388) ecords undergoing title/abstract screening (n=9964) Not relevant topic-journal title/abstract (n=8957) Not relevant topic-conference abstract (n=394) Full text-does not include CV endpoints (n=217) Prevention Cs (n=149) eviews (n=112) Pre-menopausal population (n=63) Not English (n=22) Observational (n=17) Studies meeting inclusion criteria (n=33) Cs included in the quantitative analysis (n=16)
9 Meta-Analysis of Cardiovascular Adverse Events by C Design
10 Meta-Analysis of Cardiovascular Adverse Events by C Design P N P 0 5
11 Secondary Analysis-Ischemic Heart Disease Upfront Adjuvant vs : 1.30 (95% CI: ) Extended adjuvant vs P : 1.04 (95% CI: ) Extended Adjuvant vs P : 0.91 (95% CI: ) Upfront adjuvant vs P : 0.66 (95% CI: )
12 Conclusions he increased risk of cardiovascular disease associated with s in Cs comparing s to tamoxifen should be interpreted with caution he augmented cardiovascular risk associated with s in adjuvant trials can be accounted for by the cardioprotective effects of tamoxifen his new evidence may guide the assessment of risk and benefit ratio of aromatase inhibitors and tamoxifen
13 Acknowledgements Supervisors Dr. Laurent Azoulay Dr. Samy Suissa Collaborators Dr. Kristian Filion Dr. Shatha Al-Qurashi Dr. Nathaniel Bouganim Nazi orabi
Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationSetting The study setting was secondary care. The economic study was carried out in Norway.
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationFulvestrant for hormone-sensitive metastatic breast cancer(review)
Cochrane Database of Systematic Reviews Fulvestrant for hormone-sensitive metastatic breast cancer (Review) LeeCI,GoodwinA,WilckenN LeeCI,GoodwinA,WilckenN. Fulvestrant for hormone-sensitive metastatic
More informationThe worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials
The worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials Richard Gray, for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) Main questions, 2005-6 1) 5 years of
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationForm Breast Health Supplement to the Medication Inventory (WHI Extension Study)
154 - Breast Health Supplement to the Medication Inventory (WHI ID WHI Participant Common ID Col#1 F154DAYS Days since randomization or enrollment Col#2 Days since randomization or enrollment to receipt
More informationPrescribing of endocrine therapy after breast cancer diagnosis
Prescribing of endocrine therapy after breast cancer diagnosis Gabrielle Emanuel, Katherine E Henson, John Broggio, Jackie Charman, Kieran Horgan, David Dodwell, Sarah C Darby National Cancer Registration
More informationThiazolidinediones and risk of cancer in type 2 diabetes:
Thiazolidinediones and risk of cancer in type 2 diabetes: A systematic review and meta-analysis Isabelle N. Colmers BScH, MSc Candidate TZDs and Cancer Risk in Type 2 Diabetes Thank you to Collaborators:
More informationCNODES: A Canadian Initiative
CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, Canada PROTECT Conference, EMA, London, 19 February, 2015 PROVINCE OF QUEBEC, CANADA
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationadherence research Introduction Breast cancer is the most common cancer diagnosis among women in the United States,
Psychosocial factors in adjuvant hormone therapy for breast cancer: An emerging context for adherence research Introduction Breast cancer is the most common cancer diagnosis among women in the United States,
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationBisphosphonates and other bone agents for breast cancer(review)
Cochrane Database of Systematic Reviews Bisphosphonates and other bone agents for breast cancer (Review) O Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A O Carrigan B, Wong MHF, Willson
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016
pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016 DISCLAIMER Not a Substitute for Professional Advice This
More informationExamination of the impact of shifting practice from plain film mammography to digital mammography
Examination of the impact of shifting practice from plain film mammography to digital mammography Presented by Rachel Farber Sydney Medical School, School of Public Health The University of Sydney Page
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationTHIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY
TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY Samy Suissa McGill University and Jewish General Hospital Montreal, Canada ISPE mid-year meeting, Miami April 22, 2012 STATINS REDUCE: JAMA 2000: Fracture rate
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationTrial: Take-Home Message: Executive Summary: Guidelines:
Trial: Davies C, et al. "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial".
More informationIan F Tannock MD, PhD, DSc
Reading the literature on clinical trials with a critical eye: recognizing and learning from the mistakes of others Ian F Tannock MD, PhD, DSc Professor of Medical Oncology and Medical Biophysics Princess
More informationSystematic reviews vs. rapid reviews: What s the difference?
Systematic reviews vs. rapid reviews: What s the difference? Andrea C. Tricco PhD MSc Jesmin Antony, MSc Sharon E. Straus, MD MSc CADTH Rapid Review Summit Objectives To discuss the difference between
More informationCanadian Society of Internal Medicine Annual Meeting 2018 Banff, AB
Canadian Society of Internal Medicine Annual Meeting 2018 Banff, AB Prevalence of strongyloidiasis and schistosomiasis among migrants: A systematic review and meta-analysis Xing Jian Liu Division of General
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Adjuvant tamoxifen and exemestane in postmenopausal early breast cancer Derks, Marloes GM; Blok, Erik J.; Seynaeve, Caroline; Nortier, JWR; Kranenbarg, E. M K; Liefers, GJ; Putter, Hein; Kroep, Judith
More informationSupplementary information
Supplementary information Network Meta-Analysis of The Effectiveness of Neoadjuvant Endocrine Therapy for postmenopausal, HR Positive Breast Cancer Wei Wang 1*, Chenghao Liu *, Wenbin Zhou 1, Tiansong
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationEvidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy
Evidence review for Intermittent therapy for drug-susceptible TB: Dr. Dick Menzies Montreal Chest Institute, McGill University Montreal, Canada Questions addressed: intermittent therapy 1: Does intermittent
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationA Layperson's Guide to Endocrine (Hormone) Therapy
A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy
More informationBreast Cancer Prevention for the Population at Large
Breast Cancer Prevention for the Population at Large Jack Cuzick Centre for Cancer Prevention Wolfson Institute of Preventive Medicine St Bartholomew s Medical School Queen Mary University of London London,
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationRisk of Stroke in Older Women Treated for Early Invasive Breast Cancer. Tamoxifen vs. Aromatase Inhibitors:
Risk of Stroke in Older Women Treated for Early Invasive Breast Cancer Tamoxifen vs. Aromatase Inhibitors: A Population based Retrospective Cohort Study by Don Thiwanka Dilshan Wijeratne MBBS A thesis
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationThe effect of resection of the primary tumour for stage IV colorectal cancer on patient survival: a systematic review and meta-analysis
The effect of resection of the primary tumour for stage IV colorectal cancer on patient survival: a systematic review and meta-analysis C.Clancy, J.P. Burke, M. Barry, M.F Kalady, J.C. Coffey Dept. of
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More information03/14/2019. Scope of the Problem. Objectives
Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationPodcast ESMO 2011: The Tamoxifen- Exemestane Adjuvant Multinational (TEAM) Phase III Breast Cancer Trial Results
Page 1 of 7 Contact EJCMO.tv Blog» Editorial Board The EJCMO Medical Journal About EJCMO.tv Sub-Specialties» Podcast ESMO 2011: The Tamoxifen- Exemestane Adjuvant Multinational (TEAM) Phase III Breast
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationResults. NeuRA Mindfulness and acceptance therapies August 2018
Introduction involve intentional and non-judgmental focus of one's attention on emotions, thoughts and sensations that are occurring in the present moment. The aim is to open awareness to present experiences,
More informationAdjuvant Hormonal Therapy in Peri- and Postmenopausal. Breast Cancer
Breast Cancer Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Paula D. Ryan, Paul E. Goss Massachusetts General Hospital, Boston, Massachusetts, USA Key Words. Breast cancer Aromatase
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationpan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016
pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationPresent by Dr Phuong Leung Dr Vasiliki Orgeta Professor Martin Orrell. Division of Psychiatry University College London
The effects of carer involvement in cognitionbased interventions (CBIs) for people with dementia on carer wellbeing: a systematic review and meta-analysis Present by Dr Phuong Leung Dr Vasiliki Orgeta
More informationTechnology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the firstline treatment of metastatic hormone- receptor-positive e breast cancer that overexpresses HER2 Technology appraisal guidance
More informationSupplementary Online Content
Supplementary Online Content Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. Published
More informationHormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive
Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationStrategies to increase the uptake of the influenza vaccine by healthcare workers: A summary of the evidence
Strategies to increase the uptake of the influenza vaccine by healthcare workers: A summary of the evidence This evidence summary document has been prepared for the National Collaborating Centres for Public
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationQuality and Reporting Characteristics of Network Meta-analyses: A Scoping Review
Quality and Reporting Characteristics of Network Meta-analyses: A Scoping Review Andrea C. Tricco MSc, PhD Scientist, Li Ka Shing Knowledge Institute of St. Michael s Hospital Assistant Professor, Dalla
More informationDemographics, Subgroup Analyses, and Statistical Considerations in Cluster Randomized Trials
Demographics, Subgroup Analyses, and Statistical Considerations in Cluster Randomized Trials Monique L. Anderson, MD MHS Assistant Professor of Medicine Division of Cardiology Duke Clinical Research Institute
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationProblem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More informationpan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017
pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationTranslating nutrition research into practice: a look at novel strategies to improve evidence-based diet-related decisions
Translating nutrition research into practice: a look at novel strategies to improve evidence-based diet-related decisions Sophie Desroches, RD, PhD Assistant Professor FRSQ Junior 1 Scholar Dept of Food
More informationDistraction techniques
Introduction are a form of coping skills enhancement, taught during cognitive behavioural therapy. These techniques are used to distract and draw attention away from the auditory symptoms of schizophrenia,
More information1114 employing easily measurable risk factors (3,6). Specifically, the NCEP defines the metabolic BMI ⴝ body mass index syndrome as having 3 or more o
Journal of the American College of Cardiology 2010 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 56, No. 14, 2010 ISSN 0735-1097/$36.00 doi:10.1016/j.jacc.2010.05.034
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationFulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials
Critical Reviews in Oncology/Hematology 73 (2010) 220 227 Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials Antonis Valachis
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationDrug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors Final Original Report July 2015 The purpose of reports is to make available information regarding the comparative clinical
More informationNCCP Chemotherapy Protocol
Letrozole Monotherapy INDICATIONS FOR USE: INDICATION Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. Extended adjuvant treatment of hormone-dependentinvasive
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More information